Expression of the gonadotropin genes has been shown to be modulated by pharmacological or physiological activators of both the protein kinase C (PKC) and the cAMP second messenger signaling pathways. Over the past few years, a substantial amount of progress has been made in the identification and characterization of the transcription factors and cognate cis-elements which mediate the PKC response in the LH -subunit (LH ) gene. In contrast, little is known regarding the molecular mechanisms which mediate cAMP-mediated regulation of this gene. Using pituitary cell lines, we now demonstrate that rat LH gene promoter activity is stimulated following activation of the cAMP system by the adenylate cyclase activating agent, forskolin, or by the peptide, pituitary adenylate cyclase-activating peptide. The forskolin response was eliminated with mutation of a previously identified 3′ cis-acting element for the early growth response protein-1 (Egr-1) when evaluated in the context of region −207/+5 of the LH gene. Activation of the cAMP system increased Egr-1 gene promoter activity, Egr-1 protein levels and Egr-1 binding to the LH gene promoter, supporting the role of this transcription factor in mediating the cAMP response. Analysis of a longer LH promoter construct (−797/+5) revealed additional contribution by upstream Sp1 DNA-regulatory regions. Of interest, forskolin-induced stimulation of LH gene promoter activity was observed to increase synergistically with introduction of the transcription factor, steroidogenic factor-1 (SF-1). Although SF-1 is a critical mediator of the cAMP response in other genes, mutation of the SF-1 DNA-binding sites in the rat LH gene did not alter the forskolin response nor did forskolin increase SF-1 protein levels in a gonadotrope cell line. In a further set of experiments, it was determined that forskolin-responsiveness was maintained following mutation of the previously defined homeobox-binding element at position -100. We conclude that both Egr-1 and Sp1 contribute to cAMP-dependent transcription of the rat LH gene promoter. While SF-1 does not act independently to mediate the cAMP/PKA response, SF-1 is important for magnification of this response.
Introduction
The pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), are critical mediators of sexual development and adult reproductive function. LH and FSH consist of a common -subunit linked non-covalently to one of two unique -subunits (LH and FSH respectively) . As would be predicted by their central role in reproductive physiology, expression of the gonadotropin genes is tightly regulated at both the biosynthetic and secretory levels through the complex interaction of hypothalamic, pituitary and gonadally derived factors. These factors, in turn, activate an array of intracellular signaling systems. The hypothalamic factor gonadotropin-releasing hormone (GnRH) has been widely recognized to alter gonadotropin biosynthesis via activation of both the protein kinase C (PKC) and calcium pathways (Stojilkovic et al. 1994 , Garrel et al. 1997 , Saunders et al. 1998 , Weck et al. 1998 . Recent evidence suggests that GnRH may also stimulate the cAMP/protein kinase A (PKA) signaling system 3 (Stanislaus et al. 1994 , Liu et al. 2002 . Gonadotropin gene expression is further modulated by additional hypothalamic peptides, including pituitary adenylate-cyclase activating peptide (PACAP). PACAP is a member of the vasoactive intestinal peptide/secretin/glucagon family of peptides. As its name suggests, PACAP activates the cAMP/PKA system by binding to specific cellsurface G-protein coupled receptors (Miyata et al. 1989 , Tsujii et al. 1994 .
A number of studies have pointed towards a role for the cAMP/PKA system in modulating expression of the LH gene. In early investigations, pharmacological activation of the adenylate cyclase system was shown to increase steady-state LH mRNA levels (Starzec et al. 1986 (Starzec et al. , 1989 . This cAMP-induced increase was blocked by the transcriptional inhibitor, actinomycin D, consistent with an effect of this signaling system on LH gene promoter activity (Park et al. 1997 ). In subsequent experiments, which utilized the somatolactotrope GH 3 cell line, LH gene promoter activity was reported to be increased by cell-permeable cAMP analogues and by the adenylate-cyclase activating agent, forskolin; however, these observations were not confirmed in gonadotrope cells (Clayton et al. 1991 , Saunders et al. 1998 . Together, these results strongly suggest the presence of a cAMP-inducible regulatory element(s) in the LH gene promoter; however, no subsequent progress has been made in identifying this site(s). This lack of progress contrasts with the advances achieved in the characterization of the transcription factors which are critical for basal and GnRH-stimulated expression of the LH gene in a variety of species (Fig. 1) . The DNA-binding sites for three of these transcription factors, steroidogenic factor-1 (SF-1), early growth response protein-1 (Egr-1) and Sp1, form a tripartite response element in the rat LH gene promoter which confers GnRH-responsiveness (Kaiser et al. 2000) . Interestingly, each of these transcription factors has been implicated in mediating cAMP-responsiveness in other genes.
Egr-1, also known as zif/268, Krox-24 and NGFI-A, is a member of the immediate early response gene family whose members are highly regulated by a variety of growth and differentiation factors (Christy et al. 1988 , Cao et al. 1990 . Two groups have demonstrated that targeted disruption of the Egr-1 gene in mice results in specific loss of LH gene expression with maintenance of normal FSH gene expression (Lee et al. 1996 , Topilko et al. 1997 . Experiments by our laboratory and others have demonstrated the ability of Egr-1 to transactivate the LH gene promoter alone and in synergy with SF-1 via two Egr-1 binding sites, which form DNA-regulatory pairs with the SF-1 cis-elements, also known as the gonadotropespecific elements (GSEs) (Lee et al. 1996 , Halvorson et al. 1998 , Wolfe & Call 1999 . Egr-1 gene expression is markedly increased by GnRH or phorbol ester treatment of pituitary cell lines, consistent with a role for Egr-1 in mediating PKC-induced stimulation of LH gene expression (Dorn et al. 1999 , Halvorson et al. 1999 , Wolfe & Call 1999 . Egr-1 gene expression may also be increased by activation of the cAMP/PKA signaling system as suggested by studies in the ovary, as well as non-reproductive systems (BernalMizrachi et al. 2000 , Espey et al. 2000 , Tai et al. 2001 .
The transcription factor, Sp1, likewise has been implicated in both basal and GnRH-stimulated expression of the LH gene through action at its two binding sites located 5 to the SF-1 and Egr-1 cis-acting elements (Kaiser et al. 1998a , Weck et al. 2000 . Sp1 binds to GC-rich sequences, which are similar to, but distinct from, the consensus Egr-1 cis-element (Berg 1992) . Constitutively expressed in a wide range of cell types, Sp1 is best known as a Figure 1 Schematic of identified and putative DNA-regulatory elements in the rat LH gene promoter. Sp1=Sp1; SF-1=steroidogenic factor-1; Egr-1=early growth response protein-1; Ptx1=pituitary homeobox 1; Otx=orthodenticle-related homeobox (Ingraham et al. 1994 , Halvorson et al. 1996 , Kaiser et al. 1998 , Rosenberg & Mellon 2002 .
regulator of basal gene transcription; however, cAMP-induced transcription of the CYP11A gene (P450 scc) has been attributed to the presence of an Sp1 binding site in addition to a GSE (Begeot et al. 1993 , Venepally & Waterman 1995 , Liu & Simpson 1997 . It is not known if Sp1 plays a similar role in mediating the cAMP/PKA response in the LH gene.
SF-1, also known as NR5A1, also has been shown to be critical for gonadotropin gene expression. An orphan member of the nuclear hormone receptor superfamily, SF-1/NR5A1 is expressed in the gonadotrope subpopulation of the anterior pituitary gland as well as in the gonads and adrenal gland (Ingraham et al. 1994 . The SF-1 DNA-regulatory region, or GSE, resembles a nuclear hormone receptor half-site and is present as two copies in the LH gene promoter (Barnhart & Mellon 1994 , Halvorson et al. 1998 , Wolfe 1999 . SF-1 has been implicated in mediating cAMP/PKA responses in a wide variety of gonadal and adrenal genes, including the CYP19 (aromatase), CYP11A (P450 scc), CYP17 and StAR genes (Lynch et al. 1993 , Clemens et al. 1994 , Michael et al. 1995 , Zhang & Mellon 1996 , Carlone & Richards 1997 , Chau et al. 1997 , Liu & Simpson 1997 , Jacob & Lund 1998 , Sandhoff et al. 1998 . Thus, SF-1, Egr-1 and Sp1 potentially may all play a role in mediating cAMP-induced expression of the LH gene.
The homeobox cis-element located at position 100 in the LH gene promoter also deserves consideration as a potential modulator of cAMP-induced LH gene transcription. This DNA-regulatory region has been shown to bind members of the Ptx (pituitary homeobox) and Otx (orthodenticle-related homeobox) families of homeobox proteins , Rosenberg & Mellon 2002 . Ptx1 is required for normal anterior pituitary development as well as for the expression of a broad array of pituitaryspecific genes (Lamonerie et al. 1996 , Lanctot et al. 1997 , Quirk et al. 2001 ). Ptx1 acts in synergy with Egr-1 and SF-1 to generate GnRH-induced transcriptional activity of the LH gene; however, this effect is thought to be the result of Ptx1 interaction with modified transcription factors, particularly Egr-1, rather than through alteration of Ptx1 gene expression itself . LH gene expression also has been demonstrated to be regulated by Otx1 and an Otx-related factor may be required for gonadotrope maturation (Acampora et al. 1998 , 1999 , Rosenberg & Mellon 2002 . Thus, while clearly critical for gonadotrope function, it is unknown whether these homeobox proteins are able to directly mediate hormonal responsiveness.
In summary, substantial progress has been made in the identification of basal and GnRH/PKCresponsive elements in the LH gene promoter. Limited data from prior studies have suggested that the cAMP/PKA system may also mediate LH gene expression; however, this observation has not been evaluated at the molecular level. In the present study, we demonstrate that activation of the cAMP/PKA system through various methods does, in fact, increase rat LH gene promoter activity in a gonadotrope-derived cell line. We then investigate the transcriptional mechanisms which mediate this response with a focus on the previously identified LH DNA-regulatory elements for Egr-1, Sp1, SF-1 and Ptx1/Otx.
Materials and methods

Electrophoretic mobility shift assay (EMSA) analysis
The nucleotide sequence of the rat LH gene promoter is based on sequencing data available at GenBank accession number AF020505, which differs slightly from that of Jameson et al. (1984) . Probes were created by T4 polynucleotide kinase end-labeling with [ -32 P]ATP followed by purification over a NICK column (Pharmacia Biotech, Uppsala, Sweden). A double-stranded oligonucleotide corresponding to region 67/ 35 of the rat LH gene promoter was used to detect Egr-1 DNA-binding (Halvorson et al. 1998 (Halvorson et al. , 1999 .
In vitro-translated Egr-1 was generated from 3·2 kb of the mouse Egr-1 cDNA (provided by D Nathans, Johns Hopkins University, Baltimore, MD) using the TNT Coupled Reticulocyte Lysate System (Promega, Madison, WI, USA). The resultant product was determined to be of appropriate size by comparison with [ 35 S]methionine-labeled protein markers using SDS-PAGE. The method of Andrews & Faller (1991) was used to prepare crude nuclear extracts from the mouse gonadotrope-derived cell line, T3-1, or the rat somatolactotrope cell line, GH 3 , following treatment with vehicle or forskolin for 1 h. Protein samples were incubated with 50 000 c.p.m. of oligonucleotide probe in DNA-binding buffer (20 mM Hepes (pH 7·9), 60 mM KCl, 5 mM MgCl 2 , 10 mM phenylmethylsulfonylfluoride, 10 mM dithiothreitol, 1 mg/ml BSA and 5% (v/v) glycerol) for 30 min on ice. Where indicated, 1 ml Egr-1 polyclonal antisera (sc-110; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) was added 30 min following the addition of probe and the incubation continued for 2 h. Protein-DNA complexes were resolved on a 5% non-denaturing polyacrylamide gel in 0·5 Tris-borate-EDTA buffer and subjected to autoradiography.
Plasmids used in transfection studies
The largest LH reporter construct used for these studies contained 794 bp of the 5 -flanking sequence of the rat LH gene and the first 5 bp of the 5 -untranslated region fused to a luciferase reporter gene, pXP2 (Nordeen 1988) . Deletions in this construct were created by subcloning PCR products containing the LH promoter sequences into the pXP2 vector using BamHI/HindIII sites which were introduced by the primers (Kaiser et al. 1998b) . Mutations were introduced into the LH promoter region using the Transformer SiteDirected Mutagenesis Kit (Clontech Laboratories, Inc., Palo Alto, CA, USA). The SF-1, Egr-1 and Sp1, and Otx/Ptx mutations have been described previously and are known to eliminate DNA binding on EMSA (Kaiser et al. 1998a , Halvorson et al. 1999 , Rosenberg & Mellon 2002 .
To create GSE4-GH50, an oligonucleotide was designed containing four copies of the 5 -GSE site flanked by BamHI/BglII restriction sites (sense strand: 5 -GATCCTTTTCTGACCTTGTCTGT CTCGCCTCTGACCTTGTCTGTA-3 present as a tandem repeat). This oligonucleotide was inserted upstream of the minimal growth hormone promoter, GH50, in the pXP1 luciferase reporter plasmid (Nordeen 1988 , Suen et al. 1994 . All reporter constructs were confirmed by dideoxysequencing.
The SF-1 expression vector contains 2·1 kb of the mouse SF-1 cDNA driven by cytomegalovirus (CMV) promoter sequences in the vector, pCMV5 (provided by K L Parker, Southwestern University School of Medicine, Dallas, TX) (Lala et al. 1992) . The LBD-SF-1 expression vector lacks the ligand-binding domain of SF-1 and was created by excising the SalI-SalI region of the pCMV5-SF-1 vector. The CMV expression vectors encoding the wild-type and constitutively active G-protein -subunit (G S) protein were provided by R Iyengar, Mount Sinai School of Medicine, New York, NY (Chen & Iyengar 1994) . The Egr-1 expression vector was created by cloning 3·2 kb of the mouse Egr-1 cDNA into pCMV5 at BamHI and HindIII restriction sites (Egr-1 cDNA provided by D Nathans, Johns Hopkins University, Baltimore, MD) (Christy et al. 1988) . The Egr-luc reporter construct contains 1·2 kb of the mouse Egr-1 gene promoter sequence cloned into the SalI site of pXP2 (Egr-1 5 -flanking sequence provided by V Sukhatme, Harvard Medical School, Boston, MA) (Sukhatme et al. 1987) . The SF-1-luc expression vector contains 1885 bp upstream of the mouse SF-1 transcriptional start site in the vector pLKS -LUC and was kindly supplied by Y Sadovsky, Washington University, St Louis, MO (Woodson et al. 1997) .
Transfection experiments
Rat somatolactotrope GH 3 cells or mouse gonadotrope-derived L T2 cells were cultured to 50-70% confluence in low glucose (GH 3 ) or high glucose (L T2) Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (Invitrogen, Carlsbad, CA, USA). The L T2 cell line was generously provided by P Mellon (University of California, San Diego, CA, USA) (Turgeon et al. 1996) . For the GH 3 cell line, approximately 5 10 6 cells were suspended in 0·4 ml Dulbecco's PBS plus 5 mM glucose with the DNA to be transfected. The cells received a single electrical pulse of 240 V at a total capacitance of 1000 mF using an Invitrogen Electroporator II apparatus (Invitrogen). GH 3 cells received 1·5 µg/ well of the reporter constructs. As indicated for the GH 3 cell line, cells also received 1 µg/well of the SF-1 expression vector or an equivalent amount of the appropriate 'empty' expression vector. For the L T2 cell line, cells growing in 3·5 cm tissue culture wells were transfected with reporter plasmids (1·5 µg/well) using the calcium phosphate precipitation method. Co-transfection with an RSV--galactosidase plasmid (1 µg/well) allowed correction for differences in transfection efficiency between wells in all experiments.
Cells were treated with vehicle, forskolin (2·5 µM) (Sigma, St Louis, MO, USA), or PACAP-38 (10 nM) (Calbiochem, La Jolla, CA, USA), for 4-6 h starting approximately 40 h following transfection. In a subset of experiments, cells were treated with the selective PKA inhibitor, H-89 (10 µM), or with the PKC inhibitor, GF 109203X (5 µM), starting 1 h prior to DMSO or forskolin treatment (inhibitors obtained through LC Laboratories, Woburn, MA, USA). Cells were then harvested and the cell extracts analyzed for luciferase and -galactosidase activity (Edlund et al. 1985 , deWet et al. 1987 . Luciferase activity was normalized to the level of -galactosidase activity and results calculated as fold-change relative to expression in the control wells. Data are shown as the means S.E.M. from three to ten independent experiments.
Western blot analysis
Nuclear extracts were obtained from L T2 cells as described by Tremblay et al. (1998) . Protein concentration were determined using the BCA protein assay reagent (Pierce Chemical, Rockford, IL, USA). In vitro-translated Egr-1 and SF-1 were generated using the TNT Coupled Reticulocyte Lysate System (Promega) as described for EMSA. Nuclear proteins (5 µg) were resolved on a 10% SDS-PAGE in 25 mM Tris/250 mM glycine (TG) buffer. The protein was subsequently transferred onto 0·2 µM Protran nitrocellulose (Schleicher & Schuell, Keene, NH, USA) in TG buffer containing 20% methanol. The membrane was blocked overnight at 4 C in 5% Carnation non-fat dry milk in TBS (10 mM Tris-HCl, 0·9% NaCl, pH 7·5) and then washed with TBS-T (TBS, 0·05% Tween-20). The blot was incubated overnight at 4 C in 5% milk-TBS with a polyclonal antibody directed against SF-1 (Upstate Biotechnology, Inc., Lake Placid, NY, USA) or Egr-1 (Santa Cruz Biotechnology), diluted to 1:1000 or 1:8000 respectively. After washing with TBS-T, the blot was then incubated at room temperature for 1 h in 5% milk in TBS-T containing donkey anti-rabbit IgG-horseradish peroxidase diluted 1:1000 (Santa Cruz Biotechnology). The blot was washed with TBS-T and then TBS and developed using Western Blotting Luminol Reagent according to the manufacturer's instructions (Santa Cruz Biotechnology).
Statistical analysis
ANOVA followed by comparisons with Student's t-test was used to assess whether promoter activity was statistically different between the indicated groups. Statistical significance was set at the P,0·05 level.
Results
Activation of the cAMP/PKA signaling system stimulates LH gene expression in two pituitary cell lines
Transfection experiments were performed in two pituitary cell lines, a gonadotrope-derived cell line (L T2) and a somatolactotropic cell line (GH 3 ). L T2 cells were transiently transfected with a reporter construct containing region 794/+5 of the rat LH gene promoter. Cells were treated with PACAP, a known physiological activator of the cAMP/PKA system in gonadotrope cells. As shown in Fig. 2A , PACAP treatment modestly, but significantly, increased LH gene promoter activity relative to control wells (2-fold). Although PACAP is best known for activation of the cAMP/PKA system, it also has been shown to stimulate the phospholipase C (PLC) and calcium pathways , Hezareh et al. 1996 , Pisegna & Wank 1996 , Bresson-Bepoldin et al. 1998 . Therefore, in order to more specifically investigate the cAMP system, cells were treated with forskolin, a pharmacological activator of adenylate cyclase. As observed with PACAP treatment, luciferase activity was stimulated with the addition of forskolin (1·8-fold).
The ability of forskolin to augment LH gene promoter activity was also investigated in GH 3 cells. GH 3 cells have been used extensively to study gonadotropin gene regulation and have been found to provide qualitatively accurate observations with regards to both basal and hormonally regulated LH gene expression (Kim et al. 1990 , Clayton et al. 1991 , Kuphal et al. 1994 , Stanislaus et al. 1994 , Saunders et al. 1998 , Pinter et al. 1999 ). This cell line lacks endogenous SF-1, thereby permitting independent analysis of the effects of signaling pathways and SF-1 , Halvorson et al. 1998 .
As shown in Fig. 2B , LH gene promoter activity was significantly increased with forskolin treatment or in the presence of a constitutively active mutant form of the G S protein (3-and 2-fold respectively). Co-transfection with the CMVdriven SF-1 expression vector resulted in a 15-fold increase in luciferase activity, consistent with previously published results (Halvorson et al. 1998) . Of interest, LH promoter activity increased by nearly 50-fold in the presence of SF-1 and either forskolin or the mutant G S, demonstrating synergy between SF-1 and cAMP signaling.
We next used pharmacological inhibitors in order to formally test the specificity of forskolin in our system. As shown in Fig. 2C , neither the PKA blocking agent, H-89, nor the PKC inhibitor, GF 109203X, altered basal LH -driven luciferase activity. However, the forskolin-stimulated increase in LH promoter activity was significantly blunted by H-89, but not by GF 109203X, consistent with a specific effect of forskolin on the cAMP/PKA activity.
The LH gene promoter contains two regions which contribute to the cAMP/PKA response Sequential 5 -deletion constructs of the rat LH gene promoter were tested for forskolinresponsiveness. This analysis identified two regions which contribute to the forskolin response, the first 134 and the transcriptional start site (Fig. 3) .
Loss of the cAMP/PKA response with mutation of the Egr-1 binding sites Pharmacological or hormonal activation of the cAMP/PKA signaling system has been reported to increase Egr-1 gene expression (mRNA and/or protein levels) in the ovary and in pheochromocytoma and insulinoma cell lines (Bernal-Mizrachi et al. 2000 , Espey et al. 2000 , Tai et al. 2001 . We hypothesized that cAMP-responsiveness of the LH gene may be mediated likewise by Egr-1 acting through previously identified Egr-1 ciselements in this gene. As shown in Fig. 4 , GH 3 cells were transfected with a 207/+5 rat LH gene reporter construct present as the wild-type construct or with mutations in one or both of the Egr-1 DNA-binding sites. We have previously demonstrated that in vitro-translated Egr-1 is unable to bind to oligonucleotide probes harboring analogous mutations (Halvorson et al. 1998) . Mutation of the 3 -Egr-1 site eliminated the forskolin response, while mutation of the 5 site had no effect. Although mutation of both Egr-1 cis-elements further reduced the response, this result was not statistically different than the response in the 3 -Egr mutant construct.
The forskolin response is not attributable to the presence of SF-1 or its cognate cis-elements (GSEs) in the LH gene promoter
The proximal forskolin-responsive region identified in Fig. 3 was also noted to contain previously characterized DNA-regulatory elements for the orphan nuclear receptor, SF-1. It is clear that SF-1 cannot be implicated in the ability of forskolin treatment alone to increase LH gene promoter activity in the SF-1-deficient GH 3 cell line. Nevertheless, as ultimate interest is in the physiological regulation of gonadotrope function, it is critical to determine whether SF-1 and its associated cis-elements are involved in the observed cAMP-dependent transcription of the LH gene. SF-1 has been demonstrated to be crucial for mediating cAMP/PKA-induced increases in the Figure 3 Stepwise loss of forskolin-responsiveness with sequential 5′-deletion of the LH gene promoter. GH 3 cells were transiently transfected with varying regions of the rat LH gene promoter in the luciferase reporter vector, pXP2. Cells were treated with vehicle or 2·5 M forskolin for 4-6 h starting 40 h after transfection. Luciferase activity was normalized to RSV-driven -galactosidase activity and promoter activity was calculated as fold-change over expression in the control wells. Results are shown as the means±S.E.M. Each construct was tested in between three and ten experiments with points run in triplicate. *P<0·001.
Figure 4
Loss of the cAMP/PKA response with mutation of the Egr-1 binding sites. Transient transfection was performed in GH 3 cells using luciferase reporter constructs containing region −207/+5 of the rat LH gene promoter present as either the wild-type sequence or with mutations in one or both of the previously characterized Egr-1 DNA cis-elements. Cells were treated as in Fig. 2 . The results are presented relative to the forskolin response of the wild-type construct, which has been set at 100%. Data given as the means±S.E.M. of three independent experiments. *P<0·01 vs wild-type. transcription a variety of genes encoding enzymes in the steroidogenesis pathway (Lynch et al. 1993 , Clemens et al. 1994 , Michael et al. 1995 , Zhang & Mellon 1996 , Carlone & Richards 1997 , Chau et al. 1997 , Liu & Simpson 1997 , Jacob & Lund 1998 , Sandhoff et al. 1998 . In a number of these studies, alterations in SF-1 transactivation efficiency have been attributed to cAMP-dependent phosphorylation of the AF-2 domain of SF-1 (Crawford et al. 1997 , Jacob & Lund 1998 .
We therefore investigated whether the interaction between forskolin and SF-1 was altered with deletion of the SF-1 ligand-binding domain containing the AF-2 domain. As shown in Fig. 5A , the presence of the carboxy-truncated SF-1 construct ( LBD) markedly increased LH promoter activity, although to a lesser extent than observed with the native SF-1 (4-vs 9-fold respectively). The addition of forskolin further stimulated LH gene expression in the presence of either SF-1 construct (upper panel). The data were recalculated to evaluate whether the magnitude of the forskolin response differed depending on which SF-1 construct was present. As shown in the lower panel, the fold-change in LH promoter activity was not significantly different between constructs (approximately 3-fold with either construct), suggesting that the observed synergy between SF-1 and the cAMP system is not dependent on alterations at the carboxy-terminus of the SF-1 molecule.
As an alternative approach, we reasoned that a forskolin response should be observed in the presence of SF-1 DNA-regulatory elements if, in fact, activation of the cAMP/PKA system is directly altering SF-1 functional activity. Four copies of the rat LH 5 -GSE sequence were inserted upstream of the growth hormone minimal promoter, GH50, in the pXP1 reporter vector. As seen in Fig. 5B , these sequences conferred an SF-1 response, but failed to confer a response to forskolin (10·5-and 11·8-fold for SF-1 alone and SF-1 plus forskolin respectively).
These results suggest that the cAMP/PKA effect is unlikely to be due to direct effects on the transcription factor, SF-1. This conclusion was confirmed by transfecting cells with a construct containing point mutations in both GSE sites within the context of the native rat LH gene promoter. These mutations have been shown to eliminate SF-1 DNA-binding and SF-1-induced transactivation (Halvorson et al. 1998) . In contrast to the loss of the response to SF-1, forskolininduced stimulation was conserved in the mutated construct (1·9-vs 1·8-fold in the wild-type construct) (Fig. 5C ). These data strongly suggest that SF-1 and its cognate cis-element are not required for mediating the cAMP response in the rat LH gene promoter. 
Activation of the cAMP/PKA signaling system induces Egr-1, but not SF-1, gene expression
Results from experiments presented in Figs 4 and 5 suggest that the cAMP/PKA signaling system acts via Egr-1, but not SF-1, to stimulate LH gene expression. In order to further evaluate these observations, we asked whether activation of the cAMP system altered Egr-1 and/or SF-1 protein expression in gonadotrope cells. As shown by Western blot analysis in Fig. 6A and B, treatment of gonadotrope L T2 cells with 2·5 µM forskolin markedly increased Egr-1 protein levels, but did not alter SF-1 protein levels in this protocol. The observed induction of Egr-1 protein expression by the phorbol ester, phorbol 12-myristate 13-acetate (PMA), is consistent with previous reports (Dorn et al. 1999) .
The observed increase in Egr-1 protein levels may be due to increased Egr-1 biosynthesis and/ or post-translational modification, resulting in increased protein stability. In order to determine whether activation of the cAMP pathway system altered Egr-1 biosynthesis, pituitary cell lines were transiently transfected with a luciferase reporter construct containing 1·2 kb of the Egr-1 gene promoter. Forskolin treatment increased Egr-1 promoter activity nearly 3-fold in the L T2 cell line, with a 4-fold increase in the line GH 3 cells (Fig. 6C) . In contrast, SF-1 promoter activity was not regulated by forskolin in the GH 3 cell line (data not shown).
We next used EMSA to determine whether increased Egr1 gene expression results in altered Egr-1 DNA-binding to the rat LH gene promoter. Nuclear extracts from untreated GH 3 or gonadotrope T3-1 cells formed a single dominant band with an oligonucleotide probe spanning the 3 -Egr-1 site (Fig. 7B, lanes 2 and 7) . Prior studies utilizing specific antibodies have demonstrated the presence of the transcription factor, Sp1, in this complex (Halvorson et al. 1999 ). The addition of forskolin (2·5 or 25 µM 1 h) induced a faster migrating complex (lanes 3, 5, 8 and 10) that contained Egr-1 as shown by the addition of an Egr-1-specific antibody (lanes 4, 6, 9 and 11). The similar mobility of in vitro-translated Egr-1 (lane 1) was consistent with the presence of Egr-1 in the treated extracts.
Taken together, these results suggest that the cAMP signaling system induces Egr-1 transactivation capability, at least in part, via increased biosynthesis of the Egr-1 gene.
Sp1 DNA-binding sites contribute to the full forskolin response of the −797/+5LH gene promoter region
We then tested the importance of the Egr-1 cis-elements for cAMP/PKA-responsiveness in the context of a longer region of the rat LH gene 5 -flanking sequence ( 797/+5). As shown in Fig.  8 , the forskolin effect was significantly blunted with the introduction of point mutations into the Egr-1 sites. Nevertheless, a substantial response remained in the mutant promoter constructs suggesting the presence of a non-Egr-1, PKA-responsive regulatory region in the more distal LH gene promoter.
Figure 7
Forskolin treatment induces Egr-1 binding to rat LH gene promoter sequences. Activation of the cAMP/PKA system induces Egr-1 gene expression. EMSA was performed using in vitro-translated Egr-1 (lane 1) or nuclear extracts from GH 3 cells (left panel) or from the gonadotrope-derived T3-1 cell line (right panel). Nuclear extracts were derived from cells maintained in the absence or presence of forskolin (2·5 or 25 M for 1 h). Region −67/−35 of the rat LH gene promoter containing the 3′-Egr-1-binding site was 32 P labeled and used as a probe. Where indicated, antiserum specific for Egr-1 was added 2 h prior to electrophoresis. NE=nuclear extract; * indicates Egr-1-containing complex.
Region 451/ 386 of the rat LH gene promoter has been shown to contain two binding sites for the ubiquitous transcription factor, Sp1. These sites have been shown to contribute to both basal and GnRH-mediated LH gene expression (Kaiser et al. 1998a) . Mutation in the LH -Sp1 sites significantly decreased the forskolin response, with further blunting in a construct containing mutations in both the Sp1 and Egr-1 cis-elements. These data suggest that both Sp1 and Egr-1 contribute to the full cAMP response of the 797/ +5 rat LH gene promoter.
Mutation of the homeodomain cis-element does not alter cAMP-responsiveness in the rat LH gene
As shown in Fig. 8 , a small residual cAMP-response was noted in the 797/+5 rat LH gene promoter construct despite mutation of both the Sp1 and Egr-1 cis-elements. These results suggested a contribution by a third DNA-regulatory region. In an attempt to identify this site, we analyzed a previously identified homeodomain cis-element located at position 100 in the rat LH gene promoter. Mutation of this site did not alter the magnitude of the forskolin response, arguing against a role for Ptx/Otx-related proteins in mediating this response (data not shown).
Discussion
LH gene expression is regulated by the complex interaction of hypothalamic, pituitary and gonadal factors, which in turn activate a variety of intracellular signaling systems. GnRH-induced stimulation of the PKC system has been widely recognized and intensively investigated (Kaiser et al. 1998b , Halvorson et al. 1999 , Wolfe & Call 1999 , Weck et al. 2000 , Vasilyev et al. 2002 . Studies have suggested that gonadotrope function is also mediated by physiological modulators of the cAMP/PKA system. The hypothalamic peptide, PACAP, is perhaps the best studied of these factors. PACAP has been shown to increase cAMP levels in both primary pituitary cells as well as in gonadotrope cell lines (Miyata et al. 1989 . Interestingly, GnRH has recently been demonstrated to activate G s protein and increase intracellular cAMP levels in the gonadotrope L T2 cell line, confirming prior studies in GH 3 cells stably expressing the GnRH receptor (Stanislaus et al. 1994 , Liu et al. 2002 . As reported by Ortmann et al. (1999) the gonadal steroid, estradiol, may also modulate adenylate cyclase activity. Furthermore, it is increasingly clear that crosstalk occurs between the PKC and PKA systems in the gonadotrope , Garrel et al. 1997 . Collectively, these data strongly support the physiological relevance of the cAMP/ PKA pathway in regulating gene expression in gonadotrope cells. In prior studies, PACAP has been shown to increase gonadotropin secretion and to modulate steady-state -, LH -and FSH -subunit mRNA levels , Tsujii & Winters 1995 , Winters et al. 1997 , Attardi & Winters 1998 , Burrin et al. 1998 , Fujii et al. 2002 . We now demonstrate PACAP increases LH gene promoter activity in the gonadotrope-derived cell line, L T2 (Fig. 2) . These results suggest that increased transcriptional activity contributes to the observed PACAPinduced increase in LH mRNA levels. As previously noted, PACAP stimulates the PLC and calcium pathways in addition to increasing Figure 8 Both Egr-1 and Sp1 DNA-binding sites contribute to the full cAMP response of region −797/+5 of the LH gene promoter. GH 3 cells were transiently transfected with region −797/+5 of the rat LH gene promoter present as the wild-type sequence or with mutations in the previously described Egr-1 and Sp1 cis-elements. Forskolin treatment and data calculation were as described in Fig. 5B and represent seven independent experiments. The results are presented relative to the forskolin-response of the wild-type construct, which has been set at 100%. *P<0·05 vs wild-type. intracellular cAMP levels , Hezareh et al. 1996 , Pisegna & Wank 1996 , Bresson-Bepoldin et al. 1998 . In order to focus our studies on the effects of the cAMP/PKA signaling system, we chose to utilize the specific adenylate cyclase activator, forskolin, for the remainder of our experiments.
Forskolin treatment stimulated LH gene promoter activity in both L T2 and GH 3 cells (Fig.  2) . Forskolin increased Egr-1 promoter activity, protein levels, and Egr-1 binding to the LH gene promoter (Figs 6 and 7) . Furthermore, mutation of the 3 -Egr-1 cis-element in the proximal LH gene promoter was observed to blunt the forskolin response (Fig. 4) . Based on these data, we propose that cAMP/PKA-induced stimulation of LH promoter activity is achieved, in part, through induction of Egr-1 gene expression.
It should be noted that two other groups did not observe a forskolin-mediated increase in steadystate Egr-1 mRNA levels or Egr-1 gene promoter activity using the gonadotrope-derived T3-1 cell line , Duan et al. 2002 . Interestingly, one of these groups did observe that GnRH-induced increases in Egr-1 transcription and protein levels could be partially abrogated by the PKA blocking agent, H-89, results which support a role for cAMP/PKA in modulating Egr-1 gene function (Duan et al. 2002) .
Egr-1 is a member of the immediate early gene family whose members are markedly regulated at the biosynthetic and post-translational level by a wide variety of growth and differentiation factors (Christy et al. 1988 , Cao et al. 1990 ). Forskolin treatment has been shown to increase Egr-1 promoter and protein expression in insulinoma and pheochromocytoma cell lines respectively (BernalMizrachi et al. 2000 , Tai et al. 2001 . Richards and co-workers (Espey et al. 2000) have shown that Egr-1 mRNA and protein levels are increased by human chorionic gonadotropin (hCG) treatment in ovarian granulosa cells, presumably due to LH receptor-mediated activation of the cAMP pathway. More recently, Yoshino et al. (2002) demonstrated that both hCG and 8-Br-cAMP increase Egr-1 mRNA levels in luteinized granulosa cells. Thus, current data now exist to suggest that cAMP modulates Egr-1 gene expression at multiple levels of the reproductive axis.
Mutation of the Sp1 DNA-binding sites further blunted the cAMP response in the context of the longer region of the rat LH gene promoter (Fig.  8) . Constitutively expressed, Sp1 classically has been thought to act as a basal transcription factor. Nevertheless, recent studies have implicated Sp1 in the hormonal regulation of a variety of genes, including cAMP-induced transcription of the CYP17 and CYP11A (P450 scc) steroidogenic genes (Begeot et al. 1993 , Venepally & Waterman 1995 , Borroni et al. 1997 , Ahlgren et al. 1999 ). The precise mechanism by which Sp1 mediates the cAMP effect in the rat LH gene remains to be determined. In preliminary studies, forskolin treatment did not alter the intensity of endogenous Sp1 binding to LH -Sp1 sites, implying that Sp1 protein levels are not altered (data not shown). Sp1 is known to be modified by N-and O-linked glycosylation as well as by phosphorylation (Jackson et al. 1990) . It has been proposed that these post-translational modifications may alter Sp1 interactions with other transcription factors, such as SF-1, and/or with specific co-activators including the cAMP-responsive co-factor, CBP/p300 (Liu & Simpson 1999) .
Unlike the highly conserved Egr-1 and SF-1 sites, the Sp1 cis-elements are not conserved across species, suggesting that each species may utilize different combinations of transcription factors to achieve cAMP-dependent stimulation of the LH gene. Of note, a DNA-regulatory site for the CCAAT-binding factor NF-Y has been characterized in the bovine LH gene promoter in the region of the Sp1 sites of the rat gene (Keri et al. 2000) . NF-Y has been shown to contribute to cAMP-dependent regulation of both the rat fatty acid synthase and TIMP-2 genes (Roder et al. 1997 , Zhong et al. 2000 . It would be of interest to evaluate whether the NF-Y cis-acting elements mediate cAMP-responsiveness in the bovine LH gene.
The orphan nuclear receptor SF-1 is known to alter LH gene expression independently, as well as through interactions with other transcription factors and with the PKC signaling system (Halvorson et al. 1996 , 1999 , Keri & Nilson 1996 , Dorn et al. 1999 , Wolfe 1999 ). We now demonstrate that the presence of SF-1 augments cAMP-induced stimulation of the rat LH gene promoter activity when tested in SF-1-deficient GH 3 cells. A similar observation has been reported for the equine LH gene in placental JEG3 cells (Heckert 2001) . SF-1 is believed to be directly responsible for conferring cAMP-dependent transcription in a number of genes, although the mechanism by which this effect is achieved remains unclear (Lynch et al. 1993 , Clemens et al. 1994 , Michael et al. 1995 , Zhang & Mellon 1996 , Carlone & Richards 1997 , Chau et al. 1997 , Liu & Simpson 1997 , Jacob & Lund 1998 , Sandhoff et al. 1998 , Aesoy et al. 2002 . In a variety of studies in non-pituitary cells, neither hormonal nor pharmacological stimulation of the cAMP/PKA pathway increased steady-state SF-1 mRNA levels (Zhang & Mellon 1996 , Chau et al. 1997 , Aesoy et al. 2002 . Aesoy et al. (2002) have shown that prolonged forskolin treatment (10 µM 24 h) increases SF-1 protein levels by decreasing SF-1 degradation in adrenocortical cells. We did not observe a forskolinmediated increase in gonadotrope-derived SF-1 protein (Fig. 7) ; however, we cannot rule out the possibility that a higher dose and/or longer treatment regimen would increase pituitary SF-1. Nevertheless, this response would not explain the ability of forskolin to induce LH gene transcription in the 4 h time course demonstrated in our studies. Furthermore, the persistent cAMP response with mutation of the LH -GSEs and the inability of a GSE-multimer construct to confer cAMPresponsiveness argue against a direct role for SF-1 or its cis-element (Fig. 5) . Our results strongly suggest that cAMP-induced activation of the LH gene does not require SF-1 or its cis-elements; however, the presence of SF-1 does amplify the cAMP response, probably through known functional interactions with Egr-1 and Sp1 (Liu & Simpson 1997 , Halvorson et al. 1998 , Kaiser et al. 2000 .
The studies reported here clearly indicate the complexity of the molecular mechanisms which mediate cAMP-stimulated LH gene expression. Based on our data, the Egr-1 and Sp1 sites contribute nearly 75% of cAMP-responsiveness to the LH gene promoter; however, despite mutation of the only other identified cis-element in this gene (the Ptx/Otx element), we have been unable to account for the residual response. By sequence analysis, the LH gene lacks a classic cAMPresponse element. Furthermore, mutation of a putative AP-2-like site at position 84 does not alter cAMP-mediated LH promoter activity (data not shown). It will be of interest to attempt to identify any additional cAMP-responsive ciselements in future studies.
In conclusion, our results demonstrate that activation of the cAMP system by PACAP or forskolin increases LH gene promoter activity. The forskolin response is mediated via Egr-1 and Sp1 acting at their cognate DNA-binding sites in the rat LH gene. Although not required for cAMP-responsiveness, SF-1 markedly augments cAMP-induced LH gene transcription. Of note, this mechanism is similar to a model proposed for GnRH/PKC-induced activation of the rat LH gene (Kaiser et al. 2000) . We, therefore, propose that Sp1, Egr-1 and SF-1 play critical roles in integrating the transcriptional response of the LH -subunit gene to a variety of hormonal stimuli.
